Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab
  6. Summary
       DK0010272202

GENMAB

 SummaryChartsNewsRatingsCalendarCompany 
Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the... 
Sector
Biotechnology & Medical Research
Calendar
12/14 | 02:00pmPresentation
More about the company
Ratings of Genmab
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about GENMAB
12/02Genmab A/S has published its Articles of Association
AQ
12/01Berenberg Initiates Coverage on Genmab With Sell Rating
MT
11/22GENMAB A/S : Grant of Restricted Stock Units to Board Members and Employees and Grant of W..
PU
11/22Transactions with shares and linked securities in Genmab A/S made by managerial employe..
AQ
11/22Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to..
AQ
11/18Genmab A/S has published its Articles of Association
AQ
11/16Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/16GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise - Form 6-..
PU
11/10Genmab Investor Presentation - November 2021
PU
11/10Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.
CI
11/10Genmab First Nine Months 2021 Results Presentation
PU
11/10Genmab Announces Financial Results for the First Nine Months of 2021
AQ
11/04Genmab Lifts FY21 Revenue Guidance on Higher Darzalex Royalties
MT
11/04Company Announcement - Form 6-K
PU
11/04Genmab Improves its 2021 Financial Guidance
GL
More news
News in other languages on GENMAB
12/01GENMAB : en léger recul, Berenberg juge le titre cher
12/01OPINIONES DE LOS ANALISTAS DEL DÍA : Twitter, Ferrari, Telefonica, Diageo, ENI, Kone, Prox..
12/01Jerome, ese gran loco
12/01AVIS D'ANALYSTES DU JOUR : Schneider, Bouygues, Ferrari, Diageo, ENI, JCDecaux, Nel...
11/10┐El miércoles es el día de la subida de precios?
More news
Analyst Recommendations on GENMAB
More recommendations
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB14.24%24 414
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819